Victory Capital Management Inc. Acquires 38,672 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Victory Capital Management Inc. boosted its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 179.5% in the fourth quarter, Holdings Channel reports. The fund owned 60,212 shares of the company’s stock after purchasing an additional 38,672 shares during the quarter. Victory Capital Management Inc.’s holdings in Nurix Therapeutics were worth $1,134,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. increased its position in Nurix Therapeutics by 11.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 572,834 shares of the company’s stock valued at $10,792,000 after acquiring an additional 61,114 shares during the last quarter. US Bancorp DE increased its position in Nurix Therapeutics by 144.7% during the fourth quarter. US Bancorp DE now owns 1,424 shares of the company’s stock valued at $27,000 after acquiring an additional 842 shares during the last quarter. Proficio Capital Partners LLC purchased a new stake in Nurix Therapeutics during the fourth quarter valued at $376,000. Bank of New York Mellon Corp increased its position in Nurix Therapeutics by 8.9% during the fourth quarter. Bank of New York Mellon Corp now owns 190,905 shares of the company’s stock valued at $3,597,000 after acquiring an additional 15,639 shares during the last quarter. Finally, Rhumbline Advisers increased its position in Nurix Therapeutics by 13.5% during the fourth quarter. Rhumbline Advisers now owns 103,233 shares of the company’s stock valued at $1,945,000 after acquiring an additional 12,315 shares during the last quarter.

Analyst Ratings Changes

A number of analysts recently commented on the company. BMO Capital Markets assumed coverage on Nurix Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $35.00 price objective for the company. Royal Bank of Canada upped their price target on Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 29th. BTIG Research started coverage on Nurix Therapeutics in a research report on Tuesday, December 10th. They issued a “buy” rating and a $35.00 price target for the company. JPMorgan Chase & Co. reduced their price target on Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. Finally, Stifel Nicolaus upped their price target on Nurix Therapeutics from $34.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. Three research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, Nurix Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $30.88.

Insider Activity at Nurix Therapeutics

In related news, insider Gwenn Hansen sold 3,690 shares of the stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $73,246.50. Following the completion of the transaction, the insider now directly owns 55,937 shares of the company’s stock, valued at approximately $1,110,349.45. This represents a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Houte Hans Van sold 2,811 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $55,798.35. Following the completion of the sale, the chief financial officer now directly owns 39,549 shares of the company’s stock, valued at $785,047.65. The trade was a 6.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 12,326 shares of company stock valued at $213,449. Insiders own 7.20% of the company’s stock.

Nurix Therapeutics Stock Up 1.8 %

NASDAQ NRIX opened at $13.90 on Thursday. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of -4.81 and a beta of 2.18. The business has a 50-day moving average price of $17.22 and a 200-day moving average price of $20.93. Nurix Therapeutics, Inc. has a twelve month low of $11.90 and a twelve month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Tuesday, January 28th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. Research analysts expect that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.